MailMyPrescriptions is a licensed and accredited US Pharmacy with the following Certifications:
Powered by GeniusRx
How does an FSA work?
Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Nepafenac ophthalmic suspension is used for the treatment of pain and inflammation associated with cataract surgery.
Safety and efficacy of topical nepafenac 0.1% ophthalmic suspension have been evaluated in 2 randomized, double-blind, placebo-controlled studies in patients undergoing cataract surgery. In these studies, patients receiving nepafenac (3 times daily beginning 1 day prior to cataract surgery and continuing on the day of surgery and for 2 weeks after surgery) were less likely than those receiving vehicle to have ocular pain and measurable signs of inflammation. About 80 and 50% of patients receiving nepafenac and vehicle, respectively, reported no ocular pain on the day after surgery.
Dosage and Administration
Nepafenac is applied topically to the eye as an ophthalmic suspension. Care should be taken to avoid contamination of the suspension container.
Nepafenac ophthalmic suspension should be shaken well prior to administration. The suspension should not be administered while wearing contact lenses.
Nepafenac ophthalmic suspension may be used in conjunction with other topical ophthalmic medications such as β-adrenergic blocking agents, carbonic anhydrase inhibitors, α-agonists, cycloplegics, and mydriatics. If the patient is receiving more than one topical ophthalmic drug, the drugs should be administered 10 minutes apart from nepafenac administration.
The recommended dosage of nepafenac for the treatment of pain and inflammation associated with cataract surgery in adults and children 10 years of age or older is 1 drop of a 0.1% suspension in the affected eye(s) 3 times daily beginning one day prior to cataract surgery and continuing on the day of the surgery and for 2 weeks after surgery.
No special population recommendations at this time.
Known hypersensitivity to nepafenac or any ingredient in the formulation or to other nonsteroidal anti-inflammatory agents (NSAIAs).
NSAIAs may inhibit platelet aggregation and prolong bleeding time. Some reports indicate that ophthalmic NSAIAs may cause increased bleeding of ocular tissues (including hyphemas) when used in conjunction with ocular surgery. Ophthalmic NSAIAs, including nepafenac, should be used with caution in patients with underlying bleeding tendencies or in those receiving drugs known to prolong bleeding time.
Cross-sensitivity may exist with aspirin, phenylacetic acid derivatives, and other NSAIAs. Nepafenac ophthalmic suspension should be used with caution in patients with a history of hypersensitivity to these drugs. For further discussion of cross-sensitivity of NSAIAs, see Cautions: Sensitivity Reactions in the Salicylates General Statement 28:08.04.24.
All topical NSAIAs may slow or delay wound healing.(See Drug Interactions: Topical Corticosteroids.)
Use of topical NSAIAs may result in keratitis. In some susceptible patients, continued use of topical NSAIAs also may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation; these events may be sight-threatening. Patients presenting with evidence of corneal epithelial breakdown should be advised to discontinue topical NSAIA therapy immediately and should be closely monitored for corneal health.
Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for developing adverse corneal effects that may become sight-threatening. Topical NSAIAs should be used with caution in these patients.
Use of topical NSAIAs more than 1 day prior to surgery or use beyond 14 days postoperatively may precipitate or exacerbate adverse corneal effects.
In clinical studies, nepafenac ophthalmic suspension had no substantial effect on intraocular pressure; however, changes in intraocular pressure may occur following cataract surgery.
Category C. Avoid use in late pregnancy because of known effects on fetal cardiovascular system (possible closure of the ductus arteriosus).
Nepafenac (administered orally as a single 3-mg/kg dose) is distributed into milk in rats. It is not known whether nepafenac is distributed into human milk following topical application to the eye; caution if used in nursing women.
Safety and efficacy not established in children younger than 10 years of age.
No substantial differences in safety and efficacy relative to younger adults.
Common Adverse Effects
Adverse effects reported in 1% or more of patients receiving nepafenac ophthalmic suspension include capsular opacity, decreased visual acuity, ocular foreign body sensation, increased intraocular pressure, ocular sticky sensation, conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, vitreous detachment, headache, hypertension, nausea, vomiting, and sinusitis.
Drugs Metabolized by Hepatic Microsomal Enzymes
Pharmacokinetic interaction unlikely. Nepafenac did not inhibit the in vitro metabolism of cytochrome P-450 (CYP) isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4.
Pharmacokinetic interaction unlikely.
Potential pharmacologic interaction (increased potential for wound-healing complications).(See Wound-healing Complications under Warnings/Precautions: General Precautions, in Cautions.)